title: Combined radiochemotherapy with docetaxel in patients with unresectable locally advanced head and neck tumors.
abstract: BACKGROUND
  As the treatment with docetaxel in metastatic head and neck cancer resulted in an encouraging response rate, the following phase-I study examined the effects of a combined radiochemotherapy with weekly docetaxel in patients with inoperable advanced head and neck tumors.
  
  
  METHODS
  Six patients with Stage IV head and neck cancer were included into the study. Within the treatment regimen the primary tumor and the involved lymph nodes were irradiated up to a total dose of 70 Gy, the non involved cervical and supraclavicular lymph nodes received 50 Gy in conventional fractionation. Simultaneously docetaxel was given 1 hour before radiotherapy. The initial dose was 15 mg/m2.
  
  
  RESULTS
  A dose escalation was impossible because of several dose limiting toxicities (NCI-CTC) already in the first dose level. Two patients showed skin reactions Grade 4, 2 patients pulmonary complications Grade 4, 2 patient neurologic side effects Grade 3 and 1 a thrombocytopenia Grade 3. The response rate resulted in 3 complete and 1 partial remission, 1 death, 1 patient was not evaluable.
  
  
  CONCLUSIONS
  Unexpectedly already in the first dose level several dose limiting toxicities were evaluated. For that reason the treatment scheme is not feasible.
authors.affiliation: Klinik für Strahlentherapie und Radiologische Onkologie, Klinikum rechts der Isar, TU, München.
authors.forename: K
authors.initials: K
authors.lastname: Hesse
authors.forename: B
authors.initials: B
authors.lastname: Heinrich
authors.forename: F
authors.initials: F
authors.lastname: Zimmermann
authors.forename: R
authors.initials: R
authors.lastname: Kau
authors.forename: G
authors.initials: G
authors.lastname: Sommer
authors.forename: W
authors.initials: W
authors.lastname: Achterrath
authors.forename: M
authors.initials: M
authors.lastname: Molls
authors.forename: H J
authors.initials: HJ
authors.lastname: Feldmann
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D011879:Radiotherapy Dosage; D043823:Taxoids; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel